Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. The discovery and characterisation of small molecule modulators have aided these efforts. The Transcreener ADP² Kinase Assay meets this need as it relies on direct ADP detection to measure the activity of virtually any kinase. The method has been extensively validated for kinase discovery programs since 2007. This article provides five examples of how Transcreener allowed rapid assay development to enable screening and dose-response measurements.

The innate immunity-associated kinases targeted in the five case studies include:

• AMP-Activated Kinase (AMPK)
• Janus Kinase 1 and 3 (JAK1 and JAK3)
• TANK-Binding Kinase 1 (TBK1)
• Interleukin-1 Receptor-Associated Kinase 4 (IRAK4)
• IκB Kinase (IKK-β)